Meglumine antimoniate: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
{{SK}} Meglumine antimonate | {{SK}} Meglumine antimonate | ||
==Overview== | ==Overview== | ||
| Line 16: | Line 17: | ||
==Brand Names== | ==Brand Names== | ||
GLUCANTIM, GLUCANTIME (NOT AVAILABLE) | GLUCANTIM<sup>®</sup>, GLUCANTIME<sup>®</sup> (NOT AVAILABLE) | ||
== | ==WHO Model Prescribing Information== | ||
''' [[Meglumine antimoniate description|Description]]''' | ''' [[Meglumine antimoniate description|Description]]''' | ||
| Line 35: | Line 36: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
==References== | ==References== | ||
Revision as of 03:36, 7 January 2014
| Meglumine Antimoniate |
|---|
| GLUCANTIM® WHO Prescribing Information |
| Description |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Dosage and Administration |
| How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Meglumine antimonate
Overview
Meglumine antimoniate is a medicine used for treating leishmaniasis. It is manufactured by Aventis and sold as Glucantime in France, and Glucantim in Italy.
It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
Category
Antiparasitic
Brand Names
GLUCANTIM®, GLUCANTIME® (NOT AVAILABLE)
WHO Model Prescribing Information
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages